Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 7/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19196697 | 0.84 | RECQL (0.64) | GAARAB9ANPC1KDM4EMAPT | |
| SCHEMBL17790891 | 0.83 | GAA (0.61) | GAARAB9ANPC1KDM4EMAPT | |
| SCHEMBL1764592 | 0.83 | RAB9A (0.61) | GAARAB9ANPC1KDM4EMAPT | |
| SCHEMBL225793 | 0.83 | RECQL (0.64) | GAARAB9ANPC1KDM4EMAPT | |
| SCHEMBL1434288 | 0.83 | GAA (0.66) | GAARAB9ANPC1KDM4EMAPT | |
| SCHEMBL2405184 | 0.83 | RAB9A (0.71) | GAARAB9ANPC1KDM4EMAPT | |
| SCHEMBL1764515 | 0.83 | RAB9A (0.64) | GAARAB9ANPC1KDM4EMAPT | |
| SCHEMBL9528793 | 0.83 | KDM4E (0.63) | GAARAB9ANPC1KDM4EMAPT | |
| SCHEMBL9728319 | 0.83 | GAA (0.61) | GAARAB9ANPC1KDM4EMAPT | |
| SCHEMBL9571659 | 0.83 | KDM4E (0.59) | GAARAB9ANPC1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| EP-3573959-B1 | BENZYLAMINOPYRAZINYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-07-28 | — | — | EP | disclosed |
| EP-3573952-B1 | BENZYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICALCOMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-07-14 | — | — | EP | disclosed |
| EP-3573965-B1 | INDANYLAMINOPYRAZINYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2021-06-23 | — | — | EP | disclosed |
| US-10919859-B2 | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-02-16 | — | — | US | disclosed |
| US-20190352266-A1 | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-11-21 | — | — | US | disclosed |
| US-10364267-B2 | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-05-16 | — | — | US | disclosed |
| EP-2367798-B1 | PYRAZOLONE DERIVATIVES USEFUL IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UNIV NORTHWESTERN (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20080193679-A1 | Optical anisotropic layer | FUJIFILM CORPORATION (JP) | 2008-08-14 | — | — | US | disclosed |
| US-20080186443-A1 | Liquid Crystal Composition, Retardation Plate, and Elliptic Polarizing Plate | FUJIFILM CORPORATION (JP) | 2008-08-07 | — | — | US | disclosed |
| US-20080113112-A1 | Optical Compensation Film, Method of Producing the Same, and Polarizing Plate and Liquid Crystal Display Device Using the Same | FUJIFILM CORPORATION (JP) | 2008-05-15 | — | — | US | disclosed |
| US-20080075892-A1 | Optically-Anisotropic Film and Liquid-Crystal Display Device | FUJIFILM CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080064879-A1 | Compound ,Composition And Thin Film | FUJIFILM CORPORATION (JP) | 2008-03-13 | — | — | US | disclosed |
| WO-2007101224-A2 | INHIBITORS OF THE UNFOLDED PROTEIN RESPONSE AND METHODS FOR THEIR USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070065601-A1 | Optical film, and polarizing plate and liquid crystal display device using the same | FUJI PHOTO FILM CO., LTD. (JP) | 2007-03-22 | — | — | US | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
| WO-1998017631-A2 | SUBSTITUTED OXIME-ETHERS AND THEIR USE AS PESTICIDES | NOVARTIS AG (CH) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | SSB, EBNA1BP2, PML | GAA 2575/4885RAB9A 1810/4885NPC1 1422/4885 |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GRIN2A, GRIK5, GRIN2C | GAA 869/4885RAB9A 1943/4885NPC1 485/4885 |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | GAA 3221/4885RAB9A 3956/4885NPC1 2037/4885 |
| US-10364267-B2 | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | NR1H4, GPBAR1, SLC10A1 | GAA 1028/4885RAB9A 1729/4885NPC1 41/4885 |
| US-20080193679-A1 | Optical anisotropic layer | YBX1, YBX3, H1-2 | GAA 4432/4885RAB9A 2812/4885NPC1 4740/4885 |
| US-20190142852-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | HCRTR1, NPSR1, NTSR1 | GAA 4822/4885RAB9A 1286/4885NPC1 1606/4885 |
| US-10919859-B2 | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | GPR119, GPR65, GPR52 | GAA 2977/4885RAB9A 4080/4885NPC1 1328/4885 |
| US-20080075892-A1 | Optically-Anisotropic Film and Liquid-Crystal Display Device | L1CAM, CRY1, TLN1 | GAA 4702/4885RAB9A 247/4885NPC1 1787/4885 |
| US-20080064879-A1 | Compound ,Composition And Thin Film | YBX1, H1-2, YBX3 | GAA 4565/4885RAB9A 2011/4885NPC1 4601/4885 |
| US-20190352266-A1 | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof | GPR119, GPR65, GPR52 | GAA 2977/4885RAB9A 4080/4885NPC1 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.